Search clinical trials for: 400mg Ezogabine/retigabine

Total 1733 results

GlaxoSmithKline

Completed

Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese Subjects

Epilepsy

Taiwan
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)

Not yet recruiting

Optimizing PrEP Regimens for Pregnant Women in Sub-Saharan Africa (O-PrEP Study) - Stage 1

Pregnancy | HIV | Prevention

Malawi, Zimbabwe
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Study on Safety, Absorption and Metabolism of SYHA1402 Tablets in Healthy People

Diabetic Neuropathy Peripheral

China
GlaxoSmithKline

Terminated

Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures

Epilepsy

Thailand, Korea, Republic of, Singapore, Hong Kong, Taiwan, Malaysia, Philippines
Inmagene LLC

Completed

Study to Evaluate IMG-004 in Healthy Participants

Healthy Participants

United States
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

Study of Tolerability, Safety, and Pharmacokinetics of ZL-82 in Healthy Adult Subjects.

Rheumatoid Arthritis (RA) | Inflammatory Bowel Disease - IBD1

China
GlaxoSmithKline
Bausch Health Americas, Inc.

Terminated

Study in Pediatric Subjects With Epilepsy

Epilepsy

United States
GlaxoSmithKline
Bausch Health Americas, Inc.

Terminated

Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS

Epilepsy

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

China
University Hospital of Mont-Godinne
GlaxoSmithKline; Université Catholique de Louvain

Completed

Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study (CERETI)

Epilepsy

Belgium
GlaxoSmithKline

Completed

Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304

Epilepsy, Partial
Icahn School of Medicine at Mount Sinai

Completed

Study to Treat Major Depressive Disorder (MDD) With a New Medication

Depression | Major Depressive Disorder

United States
Phloronol Inc.
Worldwide Clinical Trials

Completed

Phase I Study of PH100 (Ecklonia Cava Phlorotannins)

Safety Issues

United States
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Xuanwu Hospital, Beijing

Completed

Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets

Parkinson Disease

China
GlaxoSmithKline

Completed

Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite

Epilepsy

United States
GlaxoSmithKline

Withdrawn

Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects

Epilepsy, Partial

Japan
GlaxoSmithKline

Completed

Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial

Epilepsy

United States, Canada, Argentina, Brazil, Mexico
GlaxoSmithKline
Bausch Health Americas, Inc.

Terminated

Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures

Seizures

United States, Greece
GlaxoSmithKline

Terminated

An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures

Epilepsy

United States, France, Poland
Shanghai Vinnerna Biosciences Co., Ltd.

Withdrawn

Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets

Healthy Subjects

Australia
Xenon Pharmaceuticals Inc.

Terminated

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy (EPIK)

Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Epilepsy | Epileptic Syndromes | Disease | Epilepsy; Seizure | Epilepsy in Children

United States, Spain, Australia, Belgium, Italy
GlaxoSmithKline

Terminated

Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097

Epilepsy

Spain, Australia, Russian Federation, Israel, Belgium, Hungary, France, Germany, Poland, South Africa, Ukraine, United Kingdom
Yuhan Corporation

Completed

Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH4808 After Oral Administration in Healthy Male Subjects

Healthy

Korea, Republic of
Shanghai Jiatan Pharmatech Co., Ltd

Completed

Sudapyridine (WX-081) in Healthy Volunteers

Healthy

China
NeuroBo Pharmaceuticals Inc.
Dong-A ST Co., Ltd.

Completed

Study of DA-9801 to Treat Diabetic Neuropathy

Diabetic Neuropathy

United States
Dong-A ST Co., Ltd.

Completed

Study of DA-9801 to Treat Diabetic Neuropathic Pain

Diabetic Neuropathies

Korea, Republic of
Brian Wainger
Massachusetts General Hospital; GlaxoSmithKline; ALS Association; Harvard University

Completed

Clinical Trial of Ezogabine (Retigabine) in ALS Subjects

Amyotrophic Lateral Sclerosis

United States
Jill M Kolesar
National Cancer Institute (NCI); Novartis

Recruiting

Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma

Metastatic Melanoma | BRAF Gene Mutation

United States
National Institute of Allergy and Infectious Diseases...

Not yet recruiting

CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

Pregnancy | HIV-1-infection | Postpartum

United States, South Africa
Xenon Pharmaceuticals Inc.

Terminated

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE (EPIK-OLE)

Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Epilepsy | Epileptic Syndromes | Disease | Epilepsy; Seizure | Epilepsy in Children

United States, Australia, Belgium
SK Chemicals Co., Ltd.

Terminated

Study Phase III Study to Assess the Efficacy and Safety of SOTB07 in Asthma Patients

Asthma

Korea, Republic of
GlaxoSmithKline

Completed

A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures

Epilepsy

Thailand, Korea, Republic of, Malaysia
Bausch Health Americas, Inc.

Completed

Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)

Postherpetic Neuralgia

United States, South Africa
Bacainn Therapeutics, Inc.

Completed

A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects

Healthy Volunteers

United States
Genzyme, a Sanofi Company

Completed

ZD6474 Phase IIa Dose Finding Multicentre Study

Non Small Cell Lung Carcinoma

Japan
University Hospital, Basel, Switzerland

Completed

Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness (MDR)

Healthy

Switzerland
Vigonvita Life Sciences

Completed

Safety and Pharmacokinetics Study of Single Ascending Doses of VV116 in Healthy Volunteers

Healthy Subjects

China
GlaxoSmithKline

Completed

Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS) (IR)

Epilepsy

Bulgaria, Thailand, Russian Federation, Belgium, Italy, Ukraine, France, Germany, Netherlands, Poland
Medicines for Malaria Venture

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects

Healthy Volunteers | Malaria Falciparum | Malaria Vivax

United States
OSE Immunotherapeutics

Recruiting

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

Lymphoma | Solid Advanced Tumor

France, Belgium
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

ZL-82 Double-blind Clinical Trial

Healthy Person

China
Haudongchun Co., Ltd.

Unknown

Clinical Study to Evaluate the Efficacy of HUDC_VT in Patients With Bacterial Vaginosis

Bacterial Vaginosis | HUDC_VT | Haudongchun

Korea, Republic of
University of Washington
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Terminated

RESIST-2: 2nd-line ART for HIV-2 Infection (RESIST-2)

HIV-2 Infection

Senegal
GlaxoSmithKline
Bausch Health Americas, Inc.

Completed

Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy (RESTORE1)

Seizures

United States, Canada, Argentina, Brazil, Mexico
GlaxoSmithKline

Completed

Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures (IR)

Epilepsy

Bulgaria, Belgium, Thailand, Denmark, Russian Federation, Italy, Spain, Ukraine, Netherlands, Germany, France, Poland
Curon Biopharmaceutical (Australia) Co Pty Ltd
Novotech (Australia) Pty Limited

Terminated

A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies

Relapsed Lymphoid Malignancies | Refractory Lymphoid Malignancies

Australia
GlaxoSmithKline
Bausch Health Americas, Inc.

Completed

Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy (RESTORE2)

Seizures

Spain, Australia, Israel, Ukraine, Belgium, United States, South Africa, Hungary, United Kingdom, France, Germany, Poland, Russian Federation
St Stephens Aids Trust
University of Liverpool

Suspended

PK of Efavirenz & Lopinavir Nano-formulations in Healthy Volunteers

HIV

United Kingdom
Stiefel, a GSK Company
GlaxoSmithKline

Completed

Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis

Onychomycosis

United States, Canada, Iceland
Ensol Bioscience

Completed

Study To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects

Healthy

Korea, Republic of

Search clinical trials for: 400mg Ezogabine/retigabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations